| URL | https://www.biopharma-reporter.com/Article/2020/06 |
| Source | Biopharma |
| Date Published | 06/04/2020 |
| Author Name | Ben Hargreaves |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Company/Division name | Rentschler Biopharma |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Total number of jobs (added or to be added): | 75 |
| Year reshoring announced: | 2020 |
| Year reshoring implemented or to be implemented: | 2020 |
| Country(ies) from which reshored: | Germany |
| State(s) reshored to: | MA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | antibodies |
| What domestic positive factors made reshoring more attractive? | Proximity to customers/market, covid-19? |